AP NEWS

Myasthenia Gravis (MG) Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myasthenia Gravis (MG) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Myasthenia Gravis Report Insights

Patient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies

Myasthenia Gravis Report Key Strengths

10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition

Myasthenia Gravis Report Assessment

Current Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers

Key Topics Covered:

1. Key Insights

2. Myasthenia Gravis Market Overview at a Glance

3. Market Share (%) Distribution of MG in 2017

4. Market Share (%) Distribution of MG in 2027

5. Disease Overview: Myasthenia Gravis

6. Epidemiology and Patient Population

7. Current Treatment Practices

8. Unmet Needs

9. Marketed drugs

10. Emerging Therapies

11. Myasthenia Gravis: 7 Major Market Analysis

12. Market Outlook by Country

13. Market Drivers

14. Market Barriers

15. Appendix

Companies Mentioned

Alexion Pharmaceuticals Valent Pharmaceuticals Astellas Pharma Mitsubishi Tanabe Pharma Catalyst Pharmaceuticals CSL Behring Grifols Therapeutics, UCB Pharma Novartis Argenx Ra Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bnwf75/myasthenia_gravis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005878/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 02:01 PM/DISC: 09/26/2018 02:01 PM

http://www.businesswire.com/news/home/20180926005878/en

AP RADIO
Update hourly